HIMS & HERS HEALTH ($HIMS) posted quarterly earnings results for Q1 2026 on Monday, May 11th. The company reported earnings of -$0.18 per share, missing estimates of $0.04 by $0.22. The company also reported revenue of $608,100,000, missing estimates of $629,189,825 by $-21,089,825.
Stock price change since market close: -7.66%
You can see Quiver Quantitative's $HIMS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HIMS & HERS HEALTH Insider Trading Activity
HIMS & HERS HEALTH insiders have traded $HIMS stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 157,440 shares for an estimated $4,743,270.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,039 shares for an estimated $2,906,827.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 5 sales selling 24,194 shares for an estimated $678,255.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 13,940 shares for an estimated $445,278.
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 10,021 shares for an estimated $367,870
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
HIMS & HERS HEALTH Hedge Fund Activity
We have seen 221 institutional investors add shares of HIMS & HERS HEALTH stock to their portfolio, and 326 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FORERUNNER VENTURES MANAGEMENT, LLC removed 9,756,893 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $316,806,315
- FARALLON CAPITAL MANAGEMENT LLC removed 7,359,866 shares (-68.5%) from their portfolio in Q4 2025, for an estimated $238,974,849
- CAPITAL WORLD INVESTORS removed 4,460,282 shares (-23.7%) from their portfolio in Q4 2025, for an estimated $144,825,356
- RENAISSANCE TECHNOLOGIES LLC removed 4,278,843 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $138,934,032
- MORGAN STANLEY removed 3,346,864 shares (-46.0%) from their portfolio in Q4 2025, for an estimated $108,672,674
- TIDAL INVESTMENTS LLC removed 2,759,789 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $89,610,348
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,341,642 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $76,033,115
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HIMS & HERS HEALTH Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 12 analysts offer price targets for $HIMS in the last 6 months, with a median target of $26.5.
Here are some recent targets:
- Allen Lutz from B of A Securities set a target price of $32.0 on 04/24/2026
- Cory Carpenter from JP Morgan set a target price of $35.0 on 04/24/2026
- Jonna Kim from TD Cowen set a target price of $23.0 on 03/27/2026
- Michael Cherny from Leerink Partners set a target price of $25.0 on 03/16/2026
- Glen Santangelo from Barclays set a target price of $29.0 on 03/11/2026
- George Hill from Deutsche Bank set a target price of $28.0 on 03/10/2026
- Daniel Grosslight from Citigroup set a target price of $24.0 on 03/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
